<DOC>
	<DOC>NCT02058992</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and efficacy of ramelteon (Rozerem) when used in the routine clinical setting in patients with sleep-onset difficulty associated with insomnia.</brief_summary>
	<brief_title>Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty</brief_title>
	<detailed_description>This is a drug use surveillance planned to examine the safety and efficacy of ramelteon tablets when used in the routine clinical setting in patients with sleep-onset difficulty associated with insomnia (planned sample size, 3000) The usual adult dosage is 8 mg of ramelteon administered orally once daily at bedtime.</detailed_description>
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<criteria>1. Sleeponset difficulty associated with insomnia 1. Patients with previous history of hypersensitivity to an ingredient of Rozerem Tablets 2. Patients with severe liver dysfunction 3. Patients taking fluvoxamine maleate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>